Ranibizumab: all 350 studies that test it
Page 2 of 4. Open to participants first (6), then studies with results posted, then the rest; newest registration first within each.
- Use of Ranibizumab With Mitomycin C During TrabeculectomyCompletedNCT00661583Phase 1/2Results posted
- Ranibizumab in Preventing Failure of Ahmed Valve Glaucoma SurgeryTerminatedNCT00644280Not applicableResults posted
- Lucentis Versus Mitomycin C During Glaucoma SurgeryCompletedNCT00626782Phase 2/3Results posted
- Ranibizumab for Treatment of Persistent Diabetic Neovascularization Assessed by Wide-Field ImagingCompletedNCT00606138Phase 1/2Results posted
- Comparison of Age-related Macular Degeneration Treatments Trials: Lucentis-Avastin TrialCompletedNCT00593450Phase 3Results posted
- Ranibizumab Therapy for Non-arteritic Ischemic Optic NeuropathyCompletedNCT00561834Phase 1Results posted
- Changes in Retinal Function After Intravitreal Ranibizumab for Age-related Macular DegenerationCompletedNCT00539734Not applicableResults posted
- Lucentis for Inflammatory Macular Edema TrialCompletedNCT00498355Phase 1/2Results posted
- A Study of the Efficacy and Safety of Ranibizumab Injection in Patients With Macular Edema Secondary to Branch Retinal Vein Occlusion (BRAVO)CompletedNCT00486018Phase 3Results posted
- A Study of the Efficacy and Safety of Ranibizumab Injection in Patients With Macular Edema Secondary to Central Retinal Vein Occlusion (CRUISE)CompletedNCT00485836Phase 3Results posted
- A Study of Ranibizumab Injection in Subjects With Clinically Significant Macular Edema (ME) With Center Involvement Secondary to Diabetes Mellitus (RIDE)CompletedNCT00473382Phase 3Results posted
- A Study of Ranibizumab Injection in Subjects With Clinically Significant Macular Edema (ME) With Center Involvement Secondary to Diabetes Mellitus (RISE)CompletedNCT00473330Phase 3Results posted
- Effect of Ranibizumab on Malignant Conjunctival NeoplasiaCompletedNCT00456495Phase 1Results posted
- Laser-Ranibizumab-Triamcinolone for Proliferative Diabetic RetinopathyCompletedNCT00445003Phase 3Results posted
- Laser-Ranibizumab-Triamcinolone for Diabetic Macular EdemaCompletedNCT00444600Phase 3Results posted
- Lucentis Utilizing Visudyne (LUV Trial) Combination Therapy in the Treatment of Age-Related Macular DegenerationTerminatedNCT00423189Phase 4Results posted
- The Ranibizumab for Edema of the mAcula in Diabetes-2 (READ-2) StudyCompletedNCT00407381Phase 2Results posted
- Lucentis (Ranibizumab) for Eales' DiseaseCompletedNCT00384449Phase 2/3Results posted
- An Extension Study to Evaluate the Safety and Tolerability of Ranibizumab in Subjects With Choroidal Neovascularization Secondary to AMD or Macular Edema Secondary to RVOCompletedNCT00379795Not applicableResults posted
- Ranibizumab in Hemorrhagic Choroidal Neovascularization TrialCompletedNCT00363168Phase 1Results posted
- SUSTAIN - Study of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular DegenerationCompletedNCT00331864Phase 3Results posted
- Safety and Efficacy of Ranibizumab in Japanese Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular DegenerationCompletedNCT00284089Phase 1/2Results posted
- Safety and Efficacy of Ranibizumab in Diabetic Macular Edema With Center InvolvementCompletedNCT00284050Phase 2Results posted
- Efficacy and Safety of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD)CompletedNCT00275821Phase 3Results posted
- Laser Photocoagulation and Ranibizumab Treatment in Proliferative Diabetic RetinopathyCompletedNCT07819253Not applicable
- Intravitreal Ranibizumab for Aggressive Posterior Retinopathy of Prematurity: A Prospective Interventional Case SeriesCompletedNCT07721298Not applicable
- Outcomes of Intravitreal Ranibizumab Injection for Diabetic Vitreous HemorrhageCompletedNCT07690800Phase 4
- A Study to Evaluate the Usability of the SB11 PFS in Trial Participants With Wet AMD, Macular Oedema Secondary to RVO, or mCNVCompletedNCT07550504Phase 2
- A Study to Compare JL14002 to Lucentis® in Subjects With Wet Age-related Macular Degeneration (wAMD)CompletedNCT07389577Phase 3
- A Study to Investigate RO7200220 as Monotherapy and in Combination With Ranibizumab in Participants With Diabetic and Uveitic Macular EdemaCompletedNCT06771271Phase 1
- Ocular Safety and Usability Study for FYB201 PFSCompletedNCT06708624Phase 4
- A Efficacy and Safety Study of Ranibizumab 10mg/ml Injection (Incepta) in Patients With Diabetic Macular EdemaCompletedNCT06305416Phase 3
- Intravitreal Ranibizumab Injection for Aggressive Versus Type 1 Prethreshold Retinopathy of PrematurityCompletedNCT05701124Phase 3
- A Study of the Efficacy, Safety, and Pharmacokinetics (PK) of the Port Delivery System With Ranibizumab (PDS) in Chinese Participants With Neovascular Age-related Macular Degeneration (nAMD)Active, not recruitingNCT05562947Phase 3
- Ranibizumab Versus Aflibercept for CRVO in Young Patients.Status unknownNCT05282420Phase 4
- A Prospective Study of Ranibizumab in the Treatment of Postoperative Recurrent Vitreous Haemorrhage of Diabetic RetinopathyStatus unknownNCT05248334Phase 1
- A Study Of The Effectiveness And Safety Of A 36-Week Refill Regimen For The Port Delivery System With Ranibizumab Vs Aflibercept Treat & Extend In Subjects With Neovascular Age-Related Macular DegenerationWithdrawnNCT05126966Phase 3
- Ranibizumab Vs Bevacizumab for Type 1 Retinopathy of PrematurityStatus unknownNCT05033106Phase 3
- Effect of Ranibizumab Versus Bevacizumab on the Macular Perfusion in Diabetic Macular EdemaTerminatedNCT04991350Phase 4
- Phase I Study to Compare CMAB818 Injection and Lucentis® in Patients With Wet AMDCompletedNCT04884399Phase 1
- 601 Versus Ranibizumab in Patients With Central Retinal Vein Occlusion (CRVO)CompletedNCT04667910Phase 2
- 601 Versus Ranibizumab in Patients With Branch Retinal Vein Occlusion (BRVO)CompletedNCT04667897Phase 2
- A Study of the Efficacy, Safety, and Pharmacokinetics of a 36-Week Refill Regimen for the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration (Velodrome)Active, not recruitingNCT04657289Phase 3
- Diabetic Macular Edema (DME) Treatment With Ranibizumab and Dexamethasone or Ranibizumab Only.Status unknownNCT04601675Not applicable
- Study of Zifibancimig in Participants With Neovascular Age-related Macular DegenerationCompletedNCT04567303Phase 1/2
- Pre-vitrectomy Intravitreal Ranibizumab for Patients With Proliferative Diabetic Retinopathy Combined With Diabetic Macular EdemaStatus unknownNCT04464694Phase 4
- Comparison of Aflibercept Versus Ranibizumab in Management of Diabetic Macular Edema (DME)CompletedNCT04087746Phase 4
- Anti-VEGF Intravitreous Injections for Diabetic Macular Edema in Patients Undergoing Cataract SurgeryStatus unknownNCT04063358Phase 3
- Ranibizumab Treatment for Macular Edema Secondary to Retinal Vein OcclusionStatus unknownNCT04062370Phase 4
- Visual Outcomes and the Predictive Factors in Chinese Patients With Diabetic Macular Edema Treated With RanibizumabStatus unknownNCT03973138Phase 1/2
- Management of Patients With Neovascular Age-related Macular Degeneration Undergoing Cataract SurgeryStatus unknownNCT03944070Not applicable
- Intravitreal Ranibizumab (Lucentis®) in the Treatment of Non-leaking Macular Cysts in Retinal DystrophyCompletedNCT03763227Phase 2
- Laser (Selective Retina Therapy) and Drug Combined Intervention in Clinically Significant Diabetic Macular EdemaStatus unknownNCT03759860Phase 4
- Eylea and Lucentis for Macular Edema in Branch Retinal Vein OcclusionCompletedNCT03709745Phase 4
- Treatment of Diabetic Macular Edema (DME) With Anti-VEGF and Focal LaserCompletedNCT03590444Phase 4
- To Evaluate the Comparative Efficacy of Lucentis (Ranibizumab) 0.5mg Intravitreal Injection in Patients With Diabetic Macular Oedema (DME) With Well Controlled and Poorly Controlled Diabetes MellitusCompletedNCT03495765Phase 3
- Intravitreal Diclofenac Versus Intravitreal Ranibizumab for the Treatment of Diabetic Macular Edema.Status unknownNCT03458923Phase 4
- Multicenter Clinical Study of Anti-VEGF Treatment on High Risk Diabetic Retinopathy (DR)Status unknownNCT03452657Phase 3
- SD-OCT-guided Intravitreal Ranibizumab Treatment in Choroidal Neovascularization Due to MyopiaCompletedNCT03409250Phase 4
- Time Course of Activity Signs at SD-OCT High Frequency Intravitreal Ranibizumab Treatment in CNV Due to AMDCompletedNCT03393767Phase 4
- Evaluating of the Safety, Pharmacokinetics and Pharmacodynamics of QL1205 and Lucentis® in Patients With Wet AMDCompletedNCT03312283Phase 1
- Serum Vascular Endothelial Growth Factor in Infants With Intravitreal RanibizumabCompletedNCT03115255Not applicable
- Efficacy of Biweekly Ranibizumab (0.5 mg) for Exudative Macular Degeneration Retinal Edema Refractory to Anti-VEGFCompletedNCT03071055Phase 2
- Cytokine and Visual Outcome Variations in Eyes Receiving RanibizumabStatus unknownNCT03056092Phase 4
- Dosing Strategy of Intravitreal Ranibizumab for Pathological Myopia Choroidal NeovascularizationCompletedNCT03042871Phase 4
- Intraocular Cytokine in Recurrence of Polypoidal Choroidal VasculopathyStatus unknownNCT02976194Phase 4
- Efficacy of Fixed Monthly Dosing of Ranibizumab in Neovascular Age-related Macular DegenerationCompletedNCT02944227Phase 4
- Intravitreal Ranibizumab (Lucentis®) for Neovascular Glaucoma- a Randomized Controlled StudyStatus unknownNCT02914626Phase 3
- 24 Week Study to Compare Systemic VEGF-levels of Ranibizumab and Aflibercept in DME.WithdrawnNCT02878681Phase 4
- Comparison of PDT Combination With Ranibizumab vs. Ranibizumab Monotherapy in Persistent PCV With Initial Loading DoseStatus unknownNCT02864472Phase 4
- Intravitreal Injection of Ranibizumab Versus Sham Before Vitrectomy in Patients With Proliferative Diabetic RetinopathyCompletedNCT02857491Not applicable
- Functional and Structural Outcomes in Neovascular Age-related Macular DegenerationCompletedNCT02843490Phase 4
- Combination OZURDEX® & LUCENTIS® vs. OZURDEX® Monotherapy in Incomplete-Responders With Diabetic Macular EdemaTerminatedNCT02684084Phase 4
- Intravitreal Ranibizumab Injection as Adjuvant in the Treatment of Postvitrectomy Diabetic Vitreous Hemorrhage Accompanied by Neovascular GlaucomaCompletedNCT02647515Phase 4
- Efficacy of Ranibizumab Therapy With Aflibercept in Patients With Diabetic Macular EdemaCompletedNCT02646670Phase 4
- Intravitreal Aflibercept or Ranibizumab for Rubeosis IridisCompletedNCT02641457Phase 3
- CANadian Study in Patients With Wet AMD, Evaluating the Efficacy and Safety of Switching From Intravitreal Aflibercept to RanIbizumabWithdrawnNCT02634970Phase 4
- Study Evaluating the Safety, Pharmacokinetics and Pharmacodynamics of OPT-302 With or Without Lucentis™ in Patients With Wet AMDCompletedNCT02543229Phase 1
- Study of DS-7080a for the Treatment of Macular DegenerationCompletedNCT02530918Phase 1
- Retinal Sensitivity in BRVO After Anti-VEGF TherapyStatus unknownNCT02527733Phase 4
- Ranibizumab for Edema of the mAcula in Diabetes: Protocol 4 With Tocilizumab: The READ-4 StudyWithdrawnNCT02511067Phase 2
- Evaluation of the Usefulness of a PRN Regimen Using Ranibizumab for Macular Edema Due to Branch Retinal Vein OcclusionCompletedNCT02478515Phase 4
- 25-G Vitrectomy With Ranibizumab or Triamcinolone Acetonide on PDR in China-Randomized Clinical TrialStatus unknownNCT02447185Phase 3
- Intralesional Ranibizumab on Pterygium Vascularity, Size and Recurrence Rate: a Pilot StudyCompletedNCT02342392Phase 2/3
- Evaluation of the Simplified Treat And Extend Regimen Using Ranibizumab in Exudative Age Related Macular DegenerationStatus unknownNCT02328209Not applicable
- 25-Gauge Vitrectomy With Ranibizumab or Triamcinolone Acetonide on Proliferative Diabetic Retinopathy in ChinaStatus unknownNCT02328118Phase 2/3
- Cohort Study of the Clinical Course of Macular Diseases in KagawaStatus unknownNCT02321267Phase 4
- Prophylactic Ranibizumab for Exudative Age-Related Macular DegenerationCompletedNCT02302989Phase 1/2
- A Study to Evaluate ASP8232 in Reducing Central Retinal Thickness in Subjects With Diabetic Macular Edema (DME)CompletedNCT02302079Phase 2
- Comparison of Pharmacokinetics of and Effect on Systemic VEGF Levels in Age Related Macular Degeneration PatientsStatus unknownNCT02296567Phase 2/3
- Acute Pseudophakic Cystoid Macular Edema Treatment Trial: Intravitreal Ranibizumab Versus Triamcinolone AcetonideCompletedNCT02294656Phase 1
- A Study of the Safety and Tolerability of Intravitreal LKA651 in Patients With Diabetic Macular EdemaWithdrawnNCT02281292Phase 1
- Comparing Injection Frequency Between Aflibercept and Ranibizumab in Patients With CRVO With a Treat& Extend RegimenCompletedNCT02274259Phase 4
- Stereotactic Radiotherapy for Wet AMD (STAR)CompletedNCT02243878Phase 3
- A Pharmacokinetic Study: Ranibizumab, Aflibercept and the Effect of Vitrectomy.CompletedNCT02174211Not applicable
- Development of Intravitreal Ranibizumab by Determining the Pathogenesis of Macular Edema With Retinal Vein OcclusionStatus unknownNCT02169648Not applicable
- Ranibizumab Treatment for Age-Related Macular DegeneretionStatus unknownNCT02158624Not applicable
- Prognostic Factors for Visual Improvement in Patients Undergoing Intravitreal Ranibizumab for Retinal Vein OcclusionCompletedNCT02144662Not applicable
- Prophylactic Ranibizumab for Exudative Age-related Macular DegenerationCompletedNCT02140151Phase 1/2
- Comparing Alternative Ranibizumab Dosages for Safety and Efficacy in Retinopathy of PrematurityCompletedNCT02134457Phase 2